valproic acid has been researched along with Brain Injuries in 52 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Brain Injuries: Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.
| Excerpt | Relevance | Reference |
|---|---|---|
| "For a retrospective observational investigation based on real clinical practice of relative efficacy of valpoic acid (VPA), carbamazepine (CBZ) and topiramate (TPM) we have selected 106 patients with age of seizure onset before 17 years with a undoubted diagnosis of symptomatic or cryptogenic occipital lobe epilepsy (OLE), who had received treatment according to ILAE recommendations, and observation time since the last treatment change was from 2 to 10 years." | 9.14 | [Comparative efficacy of carbamazepine, valproic acid and topiramate in symptomatic and cryptogenic occipital lobe epilepsy in children]. ( , 2010) |
| "Here we studied the cytoprotective effect of lithium chloride and sodium valproate in the in vivo model of neonatal cerebral ischemia/hypoxia and analyzed the influence of these substances on the death of the major neurovascular unit components in experimental ischemia in vitro." | 7.83 | Protection of Neurovascular Unit Cells with Lithium Chloride and Sodium Valproate Prevents Brain Damage in Neonatal Ischemia/Hypoxia. ( Babenko, VA; Gulyaev, MV; Pevzner, IB; Pirogov, YA; Plotnikov, EY; Savchenko, ES; Silachev, DN; Sukhikh, GT; Zorov, DB; Zorova, LD, 2016) |
| "We have previously shown that resuscitation with fresh frozen plasma (FFP) in a large animal model of traumatic brain injury (TBI) and hemorrhagic shock (HS) decreases the size of the brain lesion, and that addition of a histone deacetylase inhibitor, valproic acid (VPA), provides synergistic benefits." | 7.80 | Treatment with a histone deacetylase inhibitor, valproic acid, is associated with increased platelet activation in a large animal model of traumatic brain injury and hemorrhagic shock. ( Alam, HB; Andjelkovic, AV; Bambakidis, T; Boer, C; Dekker, SE; Halaweish, I; Jin, G; Johansson, PI; Linzel, D; Liu, B; Sillesen, M, 2014) |
| "Valproic acid (VA) has been shown to be neuroprotective in several experimental brain diseases." | 5.43 | Valproic Acid Pretreatment Reduces Brain Edema in a Rat Model of Surgical Brain Injury. ( Applegate, RL; Huang, L; Khatibi, NH; Krafft, P; Martin, RD; Rolland, W; Sherchan, P; Woo, W; Zhang, J, 2016) |
| "Traumatic brain injury (TBI) and hemorrhagic shock (HS) are major causes of trauma-related deaths and are especially lethal as a combined insult." | 5.39 | Synergistic effects of fresh frozen plasma and valproic acid treatment in a combined model of traumatic brain injury and hemorrhagic shock. ( Alam, HB; deMoya, MA; DePeralta, D; Duggan, M; Hwabejire, JO; Imam, AM; Jepsen, CH; Jin, G; Liu, B; Lu, J; Sillesen, M; Socrate, S, 2013) |
| "For a retrospective observational investigation based on real clinical practice of relative efficacy of valpoic acid (VPA), carbamazepine (CBZ) and topiramate (TPM) we have selected 106 patients with age of seizure onset before 17 years with a undoubted diagnosis of symptomatic or cryptogenic occipital lobe epilepsy (OLE), who had received treatment according to ILAE recommendations, and observation time since the last treatment change was from 2 to 10 years." | 5.14 | [Comparative efficacy of carbamazepine, valproic acid and topiramate in symptomatic and cryptogenic occipital lobe epilepsy in children]. ( , 2010) |
| " As part of a large double-blind, placebo-controlled clinical trial evaluating the use of valproic acid for prophylaxis of post-traumatic seizures, we obtained extensive valproic acid concentration-time data." | 5.12 | Effect of time, injury, age and ethanol on interpatient variability in valproic acid pharmacokinetics after traumatic brain injury. ( Anderson, GD; Awan, AB; Temkin, NR; Winn, HR; Winn, RH, 2007) |
| " One hundred thirty-two patients at high risk for seizures were assigned to receive a 1-week course of phenytoin, 120 were assigned to receive a 1-month course of valproate, and 127 were assigned to receive a 6-month course of valproate." | 5.09 | Valproate therapy for prevention of posttraumatic seizures: a randomized trial. ( Anderson, GD; Awan, A; Cohen, W; Dikmen, SS; Holmes, MD; Nelson, P; Newell, DW; Temkin, NR; Wilensky, AJ; Winn, HR, 1999) |
| "Here we studied the cytoprotective effect of lithium chloride and sodium valproate in the in vivo model of neonatal cerebral ischemia/hypoxia and analyzed the influence of these substances on the death of the major neurovascular unit components in experimental ischemia in vitro." | 3.83 | Protection of Neurovascular Unit Cells with Lithium Chloride and Sodium Valproate Prevents Brain Damage in Neonatal Ischemia/Hypoxia. ( Babenko, VA; Gulyaev, MV; Pevzner, IB; Pirogov, YA; Plotnikov, EY; Savchenko, ES; Silachev, DN; Sukhikh, GT; Zorov, DB; Zorova, LD, 2016) |
| "We have previously shown that resuscitation with fresh frozen plasma (FFP) in a large animal model of traumatic brain injury (TBI) and hemorrhagic shock (HS) decreases the size of the brain lesion, and that addition of a histone deacetylase inhibitor, valproic acid (VPA), provides synergistic benefits." | 3.80 | Treatment with a histone deacetylase inhibitor, valproic acid, is associated with increased platelet activation in a large animal model of traumatic brain injury and hemorrhagic shock. ( Alam, HB; Andjelkovic, AV; Bambakidis, T; Boer, C; Dekker, SE; Halaweish, I; Jin, G; Johansson, PI; Linzel, D; Liu, B; Sillesen, M, 2014) |
| "We have previously shown that addition of valproic acid (VPA; a histone deacetylase inhibitor) to hetastarch (Hextend [HEX]) resuscitation significantly decreases lesion size in a swine model of traumatic brain injury (TBI) and hemorrhagic shock (HS)." | 3.80 | Effect of pharmacologic resuscitation on the brain gene expression profiles in a swine model of traumatic brain injury and hemorrhage. ( Alam, HB; Bambakidis, T; Dekker, SE; Jin, G; Johnson, CN; Li, Y; Liu, B; Sillesen, M, 2014) |
| "We have previously demonstrated that valproic acid (VPA), a histone deacetylase inhibitor, can improve survival after hemorrhagic shock (HS), protect neurons from hypoxia-induced apoptosis, and attenuate the inflammatory response." | 3.78 | Pharmacologic resuscitation for hemorrhagic shock combined with traumatic brain injury. ( Alam, HB; Demoya, MA; Duggan, M; Hwabejire, J; Imam, A; Jepsen, CH; Jin, G; Liu, B; Lu, J; Mejaddam, AY; Sillesen, M; Smith, WM; Socrate, S; Velmahos, GC, 2012) |
| " Replacement of phenytoin by valproic acid resulted in a 100-lb weight gain, exacerbation of sleep apnea, and right heart failure." | 3.73 | Lethal obesity associated with sodium valproate in a brain-injured patient. ( Althoff, RR; Black, DN; Daye, K; Pelletier, CA, 2005) |
| "Three patients who developed chorea during long-term treatment with valproic acid." | 3.69 | Choreiform movements associated with the use of valproate. ( Asconapé, JJ; Lancman, ME; Penry, JK, 1994) |
| "Fibrinogen was significantly increased by day 4 and returned to baseline by day 30." | 2.71 | Effect of valproate on hemostatic function in patients with traumatic brain injury. ( Anderson, GD; Chandler, WL; Temkin, NR; Winn, HR, 2003) |
| " A minimum of one steady state trough blood sample and one dosage interval urine were collected during days 3-6 and during days 7-14 post-injury." | 2.69 | Increases in metabolism of valproate and excretion of 6beta-hydroxycortisol in patients with traumatic brain injury. ( Adams, CA; Anderson, GD; Awan, AB; Temkin, NR; Winn, HR, 1998) |
| "Minimal requirements: seizure-prevention outcome given as fraction of cases; AED or control assigned by random or quasi-random mechanism." | 2.41 | Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. ( Temkin, NR, 2001) |
| "Valproic acid (VPA) is an effective drug, which is preferred for the treatments of epilepsy and various kinds of seizures." | 1.56 | Alpha-lipoic acid prevents brain injury in rats administered with valproic acid. ( Bilgin Sokmen, B; Turkyilmaz, IB; Yanardag, R, 2020) |
| "Antiepileptic prophylaxis reduces early seizures, but their use beyond 1 week does not prevent the development of post-traumatic epilepsy." | 1.43 | Antiepileptic prophylaxis following severe traumatic brain injury within a military cohort. ( Craner, M; Cranley, MR; McGilloway, E, 2016) |
| "Patients with acquired brain injuries who had taken valproate for seizures or quetiapine for delirium for >7 days (N=101)." | 1.43 | Incidence of Neutropenia With Valproate and Quetiapine Combination Treatment in Subjects With Acquired Brain Injuries. ( Kim, JY; Park, HJ, 2016) |
| "Valproic acid (VA) has been shown to be neuroprotective in several experimental brain diseases." | 1.43 | Valproic Acid Pretreatment Reduces Brain Edema in a Rat Model of Surgical Brain Injury. ( Applegate, RL; Huang, L; Khatibi, NH; Krafft, P; Martin, RD; Rolland, W; Sherchan, P; Woo, W; Zhang, J, 2016) |
| "Traumatic brain injuries (TBIs) are a major health care problem worldwide." | 1.40 | Low dose of valproate improves motor function after traumatic brain injury. ( Chiu, WT; Hung, KS; Lee, FP; Lee, WY; Lin, TJ; Shih, CL; Tai, YT; Wang, JY, 2014) |
| "Early treatment of epilepsy is warranted to avoid possible severe consequences." | 1.39 | Epilepsy and brain injury: a case report of a dramatic neuropsychiatric vicious circle. ( Angeletti, G; Carbonetti, P; Del Casale, A; Fensore, C; Ferracuti, S; Girardi, P; Kotzalidis, GD; Lazanio, S; Muzi, A; Rapinesi, C; Savoja, V; Scatena, P; Serata, D; Tatarelli, R, 2013) |
| "Traumatic brain injury (TBI) and hemorrhagic shock (HS) are major causes of trauma-related deaths and are especially lethal as a combined insult." | 1.39 | Synergistic effects of fresh frozen plasma and valproic acid treatment in a combined model of traumatic brain injury and hemorrhagic shock. ( Alam, HB; deMoya, MA; DePeralta, D; Duggan, M; Hwabejire, JO; Imam, AM; Jepsen, CH; Jin, G; Liu, B; Lu, J; Sillesen, M; Socrate, S, 2013) |
| "Fourteen patients developed seizures during that period and 25 did not." | 1.37 | Risk factors for late-onset seizures related to cerebral contusions in adults with a moderate traumatic brain injury. ( De Reuck, J, 2011) |
| " Dose-response studies revealed that systemic administration of 400 mg/kg (i." | 1.36 | Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats. ( Dash, PK; Grill, RJ; Moore, AN; Orsi, SA; Pati, S; Zhang, M; Zhao, J, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.92) | 18.7374 |
| 1990's | 6 (11.54) | 18.2507 |
| 2000's | 16 (30.77) | 29.6817 |
| 2010's | 28 (53.85) | 24.3611 |
| 2020's | 1 (1.92) | 2.80 |
| Authors | Studies |
|---|---|
| Turkyilmaz, IB | 1 |
| Bilgin Sokmen, B | 1 |
| Yanardag, R | 1 |
| Connolly, S | 1 |
| Caldwell, SB | 1 |
| Wilson, FC | 1 |
| Belozertsev, IuA | 1 |
| Zapol'skaia, IuA | 1 |
| Belozertsev, FIu | 1 |
| Iuntsev, SV | 1 |
| Rapinesi, C | 1 |
| Del Casale, A | 1 |
| Serata, D | 1 |
| Kotzalidis, GD | 1 |
| Scatena, P | 1 |
| Muzi, A | 1 |
| Lazanio, S | 1 |
| Savoja, V | 1 |
| Carbonetti, P | 1 |
| Fensore, C | 1 |
| Ferracuti, S | 1 |
| Angeletti, G | 1 |
| Tatarelli, R | 1 |
| Girardi, P | 1 |
| Yu, F | 1 |
| Wang, Z | 1 |
| Tanaka, M | 1 |
| Chiu, CT | 1 |
| Leeds, P | 1 |
| Zhang, Y | 2 |
| Chuang, DM | 1 |
| Hwabejire, JO | 2 |
| Jin, G | 5 |
| Imam, AM | 2 |
| Duggan, M | 3 |
| Sillesen, M | 8 |
| Deperalta, D | 2 |
| Jepsen, CH | 4 |
| Lu, J | 3 |
| Li, Y | 4 |
| deMoya, MA | 4 |
| Alam, HB | 8 |
| Liu, B | 6 |
| Socrate, S | 2 |
| Chen, S | 1 |
| Wu, H | 1 |
| Klebe, D | 1 |
| Hong, Y | 1 |
| Zhang, J | 3 |
| Mishra, MK | 1 |
| Beaty, CA | 1 |
| Lesniak, WG | 1 |
| Kambhampati, SP | 1 |
| Zhang, F | 1 |
| Wilson, MA | 1 |
| Blue, ME | 1 |
| Troncoso, JC | 1 |
| Kannan, S | 1 |
| Johnston, MV | 1 |
| Baumgartner, WA | 1 |
| Kannan, RM | 1 |
| Zhang, C | 1 |
| Zhu, J | 1 |
| Li, H | 1 |
| Zhao, Z | 1 |
| Liao, Y | 1 |
| Wang, X | 1 |
| Su, J | 1 |
| Sang, S | 1 |
| Yuan, X | 1 |
| Liu, Q | 1 |
| Tai, YT | 1 |
| Lee, WY | 1 |
| Lee, FP | 1 |
| Lin, TJ | 1 |
| Shih, CL | 1 |
| Wang, JY | 1 |
| Chiu, WT | 1 |
| Hung, KS | 1 |
| Dekker, SE | 3 |
| Bambakidis, T | 4 |
| Andjelkovic, AV | 1 |
| Boer, C | 1 |
| Johansson, PI | 2 |
| Linzel, D | 1 |
| Halaweish, I | 3 |
| Johnson, CN | 1 |
| Perner, A | 1 |
| Ostrowski, SR | 1 |
| Merson, TD | 1 |
| Bourne, JA | 1 |
| Cranley, MR | 1 |
| Craner, M | 1 |
| McGilloway, E | 1 |
| Bates, RC | 1 |
| Stith, BJ | 1 |
| Stevens, KE | 1 |
| Park, HJ | 1 |
| Kim, JY | 1 |
| Huang, L | 1 |
| Woo, W | 1 |
| Sherchan, P | 1 |
| Khatibi, NH | 1 |
| Krafft, P | 1 |
| Rolland, W | 1 |
| Applegate, RL | 1 |
| Martin, RD | 1 |
| Chang, Z | 1 |
| Wei, H | 1 |
| Bonthrone, T | 1 |
| Srinivasan, A | 1 |
| Bonham, T | 1 |
| Chtraklin, K | 1 |
| Silachev, DN | 1 |
| Plotnikov, EY | 1 |
| Babenko, VA | 1 |
| Savchenko, ES | 1 |
| Zorova, LD | 1 |
| Pevzner, IB | 1 |
| Gulyaev, MV | 1 |
| Pirogov, YA | 1 |
| Sukhikh, GT | 1 |
| Zorov, DB | 1 |
| Hamming, AM | 1 |
| van der Toorn, A | 1 |
| Rudrapatna, US | 1 |
| Ma, L | 1 |
| van Os, HJ | 1 |
| Ferrari, MD | 1 |
| van den Maagdenberg, AM | 1 |
| van Zwet, E | 1 |
| Poinsatte, K | 1 |
| Stowe, AM | 1 |
| Dijkhuizen, RM | 1 |
| Wermer, MJ | 1 |
| Nikolian, VC | 1 |
| Georgoff, PE | 1 |
| Piascik, P | 1 |
| Flanagan, SR | 1 |
| Elovic, EP | 1 |
| Sandel, E | 1 |
| Alisky, JM | 1 |
| Dash, PK | 1 |
| Orsi, SA | 1 |
| Zhang, M | 1 |
| Grill, RJ | 1 |
| Pati, S | 1 |
| Zhao, J | 1 |
| Moore, AN | 1 |
| Ma, CY | 1 |
| Xue, YJ | 1 |
| Li, M | 1 |
| Li, GZ | 1 |
| De Reuck, J | 1 |
| Imam, A | 1 |
| Hwabejire, J | 1 |
| Mejaddam, AY | 1 |
| Smith, WM | 1 |
| Velmahos, GC | 1 |
| Anderson, GD | 6 |
| Temkin, NR | 8 |
| Chandler, WL | 1 |
| Winn, HR | 6 |
| Barkai, G | 1 |
| Goshen, E | 1 |
| Tzila Zwas, S | 1 |
| Dolberg, OT | 1 |
| Pick, CG | 1 |
| Bonne, O | 1 |
| Schreiber, S | 1 |
| Beresford, TP | 1 |
| Arciniegas, D | 1 |
| Clapp, L | 1 |
| Martin, B | 1 |
| Alfers, J | 1 |
| Black, DN | 1 |
| Althoff, RR | 1 |
| Daye, K | 1 |
| Pelletier, CA | 1 |
| Ilhan, A | 1 |
| Iraz, M | 1 |
| Kamisli, S | 1 |
| Yigitoglu, R | 1 |
| Awan, AB | 2 |
| Winn, RH | 1 |
| Bratton, SL | 1 |
| Chestnut, RM | 1 |
| Ghajar, J | 1 |
| McConnell Hammond, FF | 1 |
| Harris, OA | 1 |
| Hartl, R | 1 |
| Manley, GT | 1 |
| Nemecek, A | 1 |
| Newell, DW | 2 |
| Rosenthal, G | 1 |
| Schouten, J | 1 |
| Shutter, L | 1 |
| Timmons, SD | 1 |
| Ullman, JS | 1 |
| Videtta, W | 1 |
| Wilberger, JE | 1 |
| Wright, DW | 1 |
| Pagulayan, KF | 1 |
| Machamer, JE | 2 |
| Dikmen, SS | 3 |
| Chandra, V | 1 |
| Spunt, AL | 1 |
| Rusinowitz, MS | 1 |
| Geracioti, TD | 1 |
| Lancman, ME | 1 |
| Asconapé, JJ | 1 |
| Penry, JK | 1 |
| Wroblewski, BA | 1 |
| Joseph, AB | 1 |
| Kupfer, J | 1 |
| Kalliel, K | 1 |
| Adams, CA | 1 |
| Wilensky, AJ | 1 |
| Holmes, MD | 1 |
| Cohen, W | 1 |
| Nelson, P | 1 |
| Awan, A | 1 |
| Lin, Y | 1 |
| Fischer, JH | 1 |
| Chatham Showalter, PE | 1 |
| Kimmel, DN | 1 |
| Yang, L | 1 |
| Benardo, LS | 1 |
| Kim, E | 1 |
| Humaran, TJ | 1 |
| Massagli, TL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Does Short-Term Anti-Seizure Prophylaxis After Traumatic Brain Injury Decrease Seizure Rates?[NCT03054285] | Phase 4 | 2,300 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | ||
| Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression: A 42-Day, Single-Site, Forced-Titration, Parallel Group, Randomized, Double-Blind, Placebo Controlled Trial[NCT00621751] | 70 participants (Actual) | Interventional | 2008-02-29 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Study physician's impression of change since study onset. Clinicians Global Impressions of Change (CGI) is a sensitive, standardized tool to assess psychopharmacologic treatment response completed by the study physician. The Global Improvement (GI) CGI subscale documented the clinician's impression of change. The GI uses a 7-point scale to assess beneficial and negative effects. Low GI values (1 -3) indicate improvement; higher values (4-7) represent worsening. (NCT00621751)
Timeframe: 42 days
| Intervention | units on a scale (Mean) |
|---|---|
| Carbamazepine | 3.1 |
| Placebo | 2.9 |
Global Impression of Change (GIC) is a 5-item Likert Scale rated participants and observer impression of change in the person with TBI. Responses range 1 = much improved to 5 = much worse. (NCT00621751)
Timeframe: 42 days
| Intervention | units on a scale (Mean) |
|---|---|
| Carbamazepine | 3.3 |
| Placebo | 3.1 |
Global Impression of Change (GIC) is a 5-item Likert Scale rated participants and observer impression of change in the person with TBI. Responses range 1 = much improved to 5 = much worse. (NCT00621751)
Timeframe: Day-42
| Intervention | score on a scale (Mean) |
|---|---|
| Carbamazepine | 3.1 |
| Placebo | 3.1 |
Neuropsychiatry Inventory-Irritability (NPI-I) & Aggression domains (NPI-A): NPI is a 40-item assessment of 12 behavioral domains (NPI-I & NPI-A domains used in this study). The most problematic aspect of each domain is graded for severity (1=mild, to 3=severe) and frequency (1-4 with 4 representing highest frequency); the domain scores (0-12) are the product of severity and frequency. To best reflect treatment target intent and meet parametric statistical method criteria, the primary outcome was a composite measure of observer-rated NPI-I & -A domains transformed to a Rasch logit scale running from 0 (best) to 100 (worse) units (i.e., observer-rated NPI-I/A Rasch construct scores). Mean day-42 observer-rated NPI-I/A Rasch construct scores were compared between placebo vs. carbamazepine using ANCOVA with baseline score as covariate. (NCT00621751)
Timeframe: 42 days
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Carbamazepine | 37.7 |
| Placebo | 36.7 |
Neuropsychiatry Inventory-Irritability (NPI-I) & Aggression domains (NPI-A): NPI is a 40-item assessment of 12 behavioral domains (NPI-I & NPI-A domains used in this study). The most problematic aspect of each domain is graded for severity (1=mild, to 3=severe) and frequency (1-4 with 4 representing highest frequency); the domain scores (0-12) are the product of severity and frequency. To best reflect treatment target intent and meet parametric statistical method criteria, a composite measure of participant-rated NPI-I & -A domains transformed to a Rasch logit scale running from 0 (best) to 100 (worse) units (i.e., participant-rated NPI-I/A Rasch construct scores). Mean day-42 participant-rated NPI-I/A Rasch construct scores were compared between placebo vs. CBZ using ANCOVA with baseline score as covariate. (NCT00621751)
Timeframe: Day 42
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Carbamazepine | 37.5 |
| Placebo | 36.4 |
Proportion of participants with Minimal Clinically Important Difference (MCID) on Neuropsychiatric Inventory Irritability-Aggression Composite Measure completed by Observer. Specifically, the proportion of participants that experienced a decrease of > 1 (MCID) in the NPI-I/A Rasch construct score (i.e., participants that are considered to have meaningful reduction in irritability/aggression) from baseline to day-42 between the groups using a chi-square test. MCID was defined as 0.5 times the standard deviation of baseline scores. (NCT00621751)
Timeframe: 42-day
| Intervention | Participants (Count of Participants) |
|---|---|
| Carbamazepine | 20 |
| Placebo | 26 |
Proportion of participants with Minimal Clinically Important Difference (MCID) on Neuropsychiatric Inventory Irritability-Aggression Composite Measure completed by Participant. Specifically, the proportion of participants that experienced a decrease of > 1 (MCID) in the NPI-I/A Rasch construct score (i.e., participants that are considered to have meaningful reduction in irritability/aggression) from baseline to day-42 between the groups using a chi-square test. MCID was defined as 0.5 times the standard deviation of baseline scores. (NCT00621751)
Timeframe: Day-42
| Intervention | Participants (Count of Participants) |
|---|---|
| Carbamazepine | 21 |
| Placebo | 16 |
5 reviews available for valproic acid and Brain Injuries
| Article | Year |
|---|---|
Valproic acid: a new candidate of therapeutic application for the acute central nervous system injuries.
Topics: Animals; Brain Injuries; Female; Humans; Male; Rats; Rats, Sprague-Dawley; Spinal Cord Injuries; Val | 2014 |
Endogenous neurogenesis following ischaemic brain injury: insights for therapeutic strategies.
Topics: Adult; Animals; Brain Injuries; Brain Ischemia; Histone Deacetylase Inhibitors; Humans; Nerve Regene | 2014 |
Coagulation changes following traumatic brain injury and shock.
Topics: Animals; Blood Coagulation; Brain Injuries; Disease Models, Animal; Humans; Platelet Activation; Sho | 2014 |
Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials.
Topics: Anticonvulsants; Brain Diseases; Brain Injuries; Carbamazepine; Controlled Clinical Trials as Topic; | 2001 |
Neurobehavioral effects of phenytoin, carbamazepine, and valproic acid: implications for use in traumatic brain injury.
Topics: Barbiturates; Brain Injuries; Carbamazepine; Cognition; Contraindications; Humans; Phenytoin; Valpro | 1991 |
7 trials available for valproic acid and Brain Injuries
| Article | Year |
|---|---|
[Comparative efficacy of carbamazepine, valproic acid and topiramate in symptomatic and cryptogenic occipital lobe epilepsy in children].
Topics: Adolescent; Anticonvulsants; Benzodiazepines; Brain Injuries; Carbamazepine; Child; Epilepsies, Part | 2010 |
Effect of valproate on hemostatic function in patients with traumatic brain injury.
Topics: Adult; Aged; Brain Injuries; Double-Blind Method; Female; Fibrinogen; Hemostasis; Humans; Male; Midd | 2003 |
Effect of time, injury, age and ethanol on interpatient variability in valproic acid pharmacokinetics after traumatic brain injury.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Craniotomy; Cytokines; | 2007 |
The measurement and magnitude of awareness difficulties after traumatic brain injury: a longitudinal study.
Topics: Adult; Anticonvulsants; Awareness; Brain Injuries; Double-Blind Method; Epilepsy; Female; Glasgow Co | 2007 |
Increases in metabolism of valproate and excretion of 6beta-hydroxycortisol in patients with traumatic brain injury.
Topics: Adult; Aged; Anticonvulsants; Brain Damage, Chronic; Brain Injuries; Female; Humans; Hydrocortisone; | 1998 |
Valproate therapy for prevention of posttraumatic seizures: a randomized trial.
Topics: Adult; Anticonvulsants; Blood Coagulation Disorders; Brain Injuries; Chemical and Drug Induced Liver | 1999 |
Neuropsychological effects of valproate in traumatic brain injury: a randomized trial.
Topics: Adolescent; Adult; Brain Injuries; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsyc | 2000 |
40 other studies available for valproic acid and Brain Injuries
| Article | Year |
|---|---|
Alpha-lipoic acid prevents brain injury in rats administered with valproic acid.
Topics: Animals; Antioxidants; Brain Injuries; Dose-Response Relationship, Drug; Female; Glutathione; Lipid | 2020 |
Maintaining community living with post brain injury agitation: a role for sodium valproate.
Topics: Adult; Aggression; Antipsychotic Agents; Aphasia; Brain Injuries; Community Integration; Humans; Mal | 2013 |
[Comparison of neuroprotective effects of anticonvulsant drugs in brain injury therapy].
Topics: Amines; Animals; Animals, Outbred Strains; Anticonvulsants; Brain; Brain Injuries; Brain Ischemia; C | 2012 |
Epilepsy and brain injury: a case report of a dramatic neuropsychiatric vicious circle.
Topics: Accidents, Traffic; Aggression; Amines; Anterior Temporal Lobectomy; Anticonvulsants; Brain Injuries | 2013 |
Posttrauma cotreatment with lithium and valproate: reduction of lesion volume, attenuation of blood-brain barrier disruption, and improvement in motor coordination in mice with traumatic brain injury.
Topics: Animals; Antimanic Agents; Blood-Brain Barrier; Brain Injuries; Disease Models, Animal; Drug Therapy | 2013 |
Pharmacologic modulation of cerebral metabolic derangement and excitotoxicity in a porcine model of traumatic brain injury and hemorrhagic shock.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Brain; Brain Injuries; Calcium; Cerebrovascular Circ | 2013 |
Synergistic effects of fresh frozen plasma and valproic acid treatment in a combined model of traumatic brain injury and hemorrhagic shock.
Topics: Animals; Brain; Brain Injuries; Female; Hemodynamics; Plasma; Resuscitation; Shock, Hemorrhagic; Swi | 2013 |
Dendrimer brain uptake and targeted therapy for brain injury in a large animal model of hypothermic circulatory arrest.
Topics: Acetylcysteine; Animals; Biological Transport; Brain; Brain Injuries; Circulatory Arrest, Deep Hypot | 2014 |
Neuroprotective and anti-apoptotic effects of valproic acid on adult rat cerebral cortex through ERK and Akt signaling pathway at acute phase of traumatic brain injury.
Topics: Animals; Apoptosis; Brain Injuries; Cerebral Cortex; Extracellular Signal-Regulated MAP Kinases; Mal | 2014 |
Low dose of valproate improves motor function after traumatic brain injury.
Topics: Acetylation; Animals; Apoptosis; Brain Injuries; Cyclic AMP Response Element-Binding Protein; Dose-R | 2014 |
Treatment with a histone deacetylase inhibitor, valproic acid, is associated with increased platelet activation in a large animal model of traumatic brain injury and hemorrhagic shock.
Topics: Animals; Brain Injuries; CD40 Ligand; Disease Models, Animal; Female; Histone Deacetylase Inhibitors | 2014 |
Effect of pharmacologic resuscitation on the brain gene expression profiles in a swine model of traumatic brain injury and hemorrhage.
Topics: Animals; Brain Chemistry; Brain Injuries; Disease Models, Animal; Female; Histone Deacetylase Inhibi | 2014 |
Effect of valproic acid and injury on lesion size and endothelial glycocalyx shedding in a rodent model of isolated traumatic brain injury.
Topics: Animals; Brain; Brain Injuries; Disease Models, Animal; Endothelium, Vascular; Glycocalyx; Histone D | 2014 |
Antiepileptic prophylaxis following severe traumatic brain injury within a military cohort.
Topics: Adult; Anticonvulsants; Brain Injuries; Carbamazepine; Case-Control Studies; Chemoprevention; Cohort | 2016 |
Increasing pro-survival factors within whole brain tissue of Sprague Dawley rats via intracerebral administration of modified valproic acid.
Topics: Animals; Apoptosis Regulatory Proteins; Biomarkers; Brain; Brain Injuries; Injections, Intraventricu | 2015 |
Incidence of Neutropenia With Valproate and Quetiapine Combination Treatment in Subjects With Acquired Brain Injuries.
Topics: Aged; Anticonvulsants; Antipsychotic Agents; Brain Injuries; Cohort Studies; Delirium; Drug Therapy, | 2016 |
Valproic Acid Pretreatment Reduces Brain Edema in a Rat Model of Surgical Brain Injury.
Topics: Animals; Behavior, Animal; Brain; Brain Edema; Brain Injuries; Disease Models, Animal; Enzyme Inhibi | 2016 |
Addition of low-dose valproic acid to saline resuscitation provides neuroprotection and improves long-term outcomes in a large animal model of combined traumatic brain injury and hemorrhagic shock.
Topics: Animals; Blotting, Western; Brain Injuries; Cognition; Disease Models, Animal; Female; Hydroxyethyl | 2015 |
Protection of Neurovascular Unit Cells with Lithium Chloride and Sodium Valproate Prevents Brain Damage in Neonatal Ischemia/Hypoxia.
Topics: Animals; Animals, Newborn; Brain Injuries; Hypoxia; Hypoxia-Ischemia, Brain; Lithium Chloride; Rats; | 2016 |
Valproate Reduces Delayed Brain Injury in a Rat Model of Subarachnoid Hemorrhage.
Topics: Animals; Brain Injuries; Disease Models, Animal; Male; Rats; Rats, Wistar; Subarachnoid Hemorrhage; | 2017 |
Valproic acid modulates platelet and coagulation function ex vivo.
Topics: Animals; Blood Coagulation; Blood Platelets; Brain Injuries; Platelet Aggregation; Shock, Hemorrhagi | 2017 |
Managing agitation associated with traumatic brain injury: behavioral versus pharmacologic interventions?
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Behavior Control; Brain Injuries; Dibenzothiazepines; | 2009 |
Minimally-responsive head injury survivors may have chronic catatonia reversed years after an accident.
Topics: Accidents; Benzodiazepines; Brain Injuries; Craniocerebral Trauma; Electroconvulsive Therapy; Fructo | 2009 |
Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats.
Topics: Acetylation; Animals; Blood-Brain Barrier; Blotting, Western; Brain Injuries; Cognition; Disease Mod | 2010 |
Sodium valproate for prevention of early posttraumatic seizures.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Brain Injuries; Epilepsy, Post-Traumatic; Female; Humans; | 2010 |
Risk factors for late-onset seizures related to cerebral contusions in adults with a moderate traumatic brain injury.
Topics: Adult; Aged; Aging; Anticonvulsants; Brain; Brain Injuries; Carbamazepine; Electroencephalography; F | 2011 |
Pharmacologic resuscitation for hemorrhagic shock combined with traumatic brain injury.
Topics: Animals; Brain Injuries; Disease Models, Animal; Drug Therapy, Combination; Female; Hemodynamics; Hy | 2012 |
Acetazolamide-enhanced neuroSPECT scan reveals functional impairment after minimal traumatic brain injury not otherwise discernible.
Topics: Acetazolamide; Adult; Brain; Brain Injuries; Carbonic Anhydrase Inhibitors; Cognition Disorders; Hum | 2004 |
Reduction of affective lability and alcohol use following traumatic brain injury: a clinical pilot study of anti-convulsant medications.
Topics: Adult; Alcoholism; Anticonvulsants; Anxiety Disorders; Brain Injuries; Carbamazepine; Female; Humans | 2005 |
Lethal obesity associated with sodium valproate in a brain-injured patient.
Topics: Adult; Anticonvulsants; Brain Injuries; Epilepsy; Fatal Outcome; Heart Failure; Humans; Male; Obesit | 2005 |
Pentylenetetrazol-induced kindling seizure attenuated by Ginkgo biloba extract (EGb 761) in mice.
Topics: Animals; Anticonvulsants; Brain; Brain Injuries; Convulsants; Ginkgo biloba; Housing, Animal; Kindli | 2006 |
Guidelines for the management of severe traumatic brain injury. XIII. Antiseizure prophylaxis.
Topics: Anticonvulsants; Brain Injuries; Humans; Phenytoin; Seizures; Time Factors; Valproic Acid | 2007 |
Treatment of post-traumatic choreo-athetosis with sodium valproate.
Topics: Adult; Athetosis; Brain Injuries; Chorea; Humans; Male; Valproic Acid | 1983 |
Valproic acid treatment of episodic explosiveness related to brain injury.
Topics: Adolescent; Aggression; Brain Injuries; Humans; Male; Neurocognitive Disorders; Valproic Acid | 1994 |
Choreiform movements associated with the use of valproate.
Topics: Adolescent; Adult; Brain Injuries; Child; Chorea; Epilepsy; Female; Humans; Male; Valproic Acid | 1994 |
Effectiveness of valproic acid on destructive and aggressive behaviours in patients with acquired brain injury.
Topics: Activities of Daily Living; Adult; Aggression; Anticonvulsants; Brain Concussion; Brain Damage, Chro | 1997 |
Incidence of intravenous site reactions in neurotrauma patients receiving valproate or phenytoin.
Topics: Adult; Aged; Anticonvulsants; Brain Injuries; Chi-Square Distribution; Double-Blind Method; Female; | 2000 |
Agitated symptom response to divalproex following acute brain injury.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antimanic Agents; Brain Injuries; Cohort | 2000 |
Valproate prevents epileptiform activity after trauma in an in vitro model in neocortical slices.
Topics: Animals; Anticonvulsants; Brain Injuries; Disease Models, Animal; Epilepsy; gamma-Aminobutyric Acid; | 2000 |
Divalproex in the management of neuropsychiatric complications of remote acquired brain injury.
Topics: Adolescent; Adult; Anticonvulsants; Bipolar Disorder; Brain Injuries; Child; Child, Preschool; Depre | 2002 |